PHARMACY

Sun sued over generic Xyzal

BY Drew Buono

GREENVILLE, N.C. UCB and Sepracor have sued Sun Pharmaceuticals in order to block the company from selling a generic version of the allergy drug Xyzal, according to Bloomberg.

Sun is seeking Food and Drug Administration approval to sell a generic of the once-daily tablet, which has the active ingredient levocetirizine. UCB and Sepracor said the generic version would violate a patent for a method of treating allergies with the compound. Sepracor owns the patent and licenses it to UCB.

The companies want a court to prevent Sun from getting Food and Drug Administration approval until the patent expires in September 2012. First-quarter sales of Xyzal were $27.9 million in the United States, Sanofi-Aventis said last month. Sanofi markets the drug in the U.S. and shares the profit with UCB.

UCB and Sepracor last month also sued Synthon over its FDA application to sell a generic Xyzal.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Bystolic fulfills pharmacists’ desire for a new beta-blocker

BY Drew Buono

NEW YORK Forest Laboratories and Mylan’s new, once-daily hypertension drug Bystolic now is available in pharmacies nationwide.

A recent survey showed that out of 20,000 retail pharmacists, 78 percent felt there was a need for a beta-blocker with an improved tolerability profile.

More than 2,000 people received Bystolic (nebivolol) during clinical trials. The drug’s efficacy was similar to that of other approved beta-blockers, the FDA said. The most common reported side effects were headache, fatigue, dizziness and diarrhea.

Hypertension affects about 72 million adults in America.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Tenn. pharmacy school receives $600,000 grant

BY Drew Buono

NASHVILLE, Tenn. Lipscomb University has received a $600,000 grant from The Memorial Foundation to support the school’s new $10.1 million pharmacy school, which will receive its first class in August, according to published reports. The Lipscomb College of Pharmacy has accepted 75 students in its first class.

The money will be used to build three patient support laboratories where students will learn to compound and prepare drugs, carry out experiments and examine and assess patients.

The school will be located in the Burton Health Sciences Center. In honor of the foundation’s grant the labs will be named The Memorial Foundation Pharmacy Practice Center.

“We believe it is a good investment for the community and for those students who want to prepare for a career in pharmacy,” said J.D. Elliott, president of The Memorial Foundation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?